No. 4 KTTA Potential Catalyst - Major News On The Treatment Front
Pasithea Therapeutics Announces Successful Treatment of First Patients in the UK with Ket-a-mine Infusion Therapy
– Pasithea Clinics commences IV ket-a-mine infusion therapy in Knightsbridge, London, for the treatment of mental health disorders –
MIAMI BEACH, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that Pasithea Clinics, its wholly owned subsidiary, has administered intravenous (“IV”) ket-a-mine therapy to its first patients. In sub-anesthetic doses, ket-a-mine has shown to be highly effective at treating some psychiatric disorders, such as treatment-resistant depression and post-traumatic stress disorder.
“With major depression the leading cause of long-term disability worldwide and mental health cases on the rise, new therapies are urgently needed for patients who do not respond to traditional treatments. Today, we are thrilled to announce that we administered our first IV ket-a-mine infusion therapy to patients with treatment-resistant depression,” stated Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics.
“This is a significant milestone for Pasithea Clinics and for patients in the U.K. suffering with mental health conditions. Decades of evidence supports the efficacy of ket-a-mine in improving symptoms for some mental health disorders, and studies have shown that up to 70% of those who receive IV ket-a-mine treatment will eventually show a clinical response. We are excited to continue providing treatment to patients deemed eligible to receive it,” concluded Dr. Reis Marques.
Read the full article here.
No. 5 KTTA Potential Catalyst - Pasithea Contacts Leading Dr-ug Development Company To Advance Dr-ug Candidate
Pasithea Therapeutics Corp. and Evotec SE Enter into Dr-ug Development Agreement
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
-- Company contracts leading global dr-ug development company to advance initial dr-ug candidate --
Miami Beach, FL / October 11, 2021 -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced the initiation of a new chemical entity (“NCE”) development program and named Evotec as its NCE research partner.
“We are delighted to be working with Evotec, one of the largest and most well-respected dr-ug discovery and development companies in the world, to progress our first compound. This is a significant step on our dr-ug development path to ultimately develop new molecular entities to improve the lives of those suffering with brain disorders. Pasithea aims to advance small molecule therapeutics with a focus on a specific neuroinflammatory pathway implicated in the neurobiology of depression and schizophrenia,” stated Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea Therapeutics.
“Evotec has a proven track record of adding value to its partners’ research by providing innovative and flexible solutions from target compound through to preclinical candidate. This is an important initial step forward for our program, and we believe that Evotec’s high-quality science and scientific execution will expedite and increase the chances of progressing our dr-ug candidate to the clinic,” stated Prof. Lawrence Steinman, Chairman of Pasithea Therapeutics.
“Pasithea is pursuing an exciting approach to target the improvement of mental health,” stated Christophe Muller, PhD, Global Head of Business Development, Evotec SE. “With our fully integrated suite of the highest quality capabilities, Evotec is uniquely equipped to facilitate the discovery and development of innovative programmes to the clinic and beyond. We are delighted to support Pasithea in addressing the very important area of mental health and look forward to working closely with the team to assist them in reaching their goal of tackling brain disorders.”
Read the full article here.
Nasdaq Biotech Recap: Important KTTA Details To Know Now
No. 1 - Pasithea Therapeutics Launches In-Home Intravenous Ket-a-mine Therapy in Major U.S. Cities
No. 2 - Low Float Profile
No. 3 - Launching Of New UK Clinic
No. 4 - Major News On The Treatment Front
No. 5 - Pasithea Contacts Leading Dr-ug Development Company To Advance Dr-ug Candidate
Coverage is officially initiated on KTTA. When you have time later, do this: